🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Chronic Myeloid Leukemia, Chronic Phase

ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants NCT06787144Phase 14 sites📍 Akita📍 Sapporo📍 Suita-shi Enliven Therapeutics · Tests: ELVN-001 A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites📍 Duarte📍 Palo Alto📍 Tampa Crossbow Therapeutics, Inc. · Tests: CBX-250 TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients NCT06088888Phase 12 sites📍 Houston📍 Seattle Shenzhen TargetRx Co., Ltd. · Tests: TGRX-678 Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in China NCT07375355n/a1 site📍 Wuhan Novartis Pharmaceuticals A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy NCT07091019n/a17 sites📍 Birmingham📍 Stockton📍 Torrance Novartis Pharmaceuticals · Tests: TKIs Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML NCT06757855Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: Olverembatinib, Venetoclax, Azacitidine A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany NCT07549516n/a69 sites📍 Baden-Baden📍 Heidenheim📍 Schwäbisch Hall Novartis Pharmaceuticals Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia NCT06629584Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Asciminib Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia NCT05282108n/a4 sites📍 Cairo📍 Cairo📍 Cairo Hikma Pharmaceuticals LLC · Tests: Carcemia, Glivec Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant NCT06059391Phase 23 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Granulocyte Colony-Stimulating Factor, Hema… Study of Olverembatinib (HQP1351) in Patients With CML-CP NCT06423911Phase 3163 sites📍 Birmingham📍 Anchorage📍 Goodyear Ascentage Pharma Group Inc. · Tests: olverembatinib, Bosutinib Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia NCT07071155EARLY Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Momelotinib, Azacitidine Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL NCT04260022Phase 19 sites📍 Birmingham📍 Duarte📍 Atlanta Ascentage Pharma Group Inc. · Tests: Ascentage Pharma HQP1351 bioavailable inhibitor, Blinatumomab Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant NCT07020533Phase 13 sites📍 Duarte📍 Atlanta📍 Boston City of Hope Medical Center · Tests: Biospecimen Collection, Electronic Health Record Review, Haploidentical Hematopoietic Cell Transplantation, Letermovir,… A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. NCT06566742Phase 22 sites📍 Miami📍 Houston M.D. Anderson Cancer Center · Tests: Olutasidenib Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation NCT03683433Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Azacitidine, Enasidenib Mesylate Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment NCT07651878Phase 11 site📍 Bergen Mendus · Tests: vididencel A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) NCT06950034Phase 17 sites📍 Stanford📍 Tampa📍 Boston Solu Therapeutics, Inc · Tests: STX-0712 Evaluation of Advanced Practice Nurse's Management of Patients With Chronic Myeloid Leukemia NCT06082804NA1 site📍 Avignon Centre Hospitalier Henri Duffaut - Avignon · Tests: APN and medical management, Medical management, Quality of life assessment, Treatment compliance assessment Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide NCT03533816Phase 12 sites📍 Westwood📍 Columbus University of Kansas Medical Center · Tests: EAGD T-cell infusion (Phase I), EAGD T-cell infusion (Expansion) Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy NCT03630991Phase 11 site📍 Houston M.D. Anderson Cancer Center · Tests: Edetate Calcium Disodium, Multivitamin, Succimer ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML NCT03595917Phase 14 sites📍 Chicago📍 Boston📍 Boston Marlise Luskin, MD · Tests: ABL001, Dasatinib, Prednisone, Blinatumomab Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib. NCT06514534Phase 26 sites📍 Bordeaux📍 Lille📍 Lyon Novartis Pharmaceuticals · Tests: ABL001/Asciminib Oral-ATO for TP53-mutated Myeloid Malignancies NCT06778187Phase 21 site📍 Hong Kong The University of Hong Kong · Tests: Oral arsenic trioxide The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP NCT06390306n/a15 sites📍 Beijing📍 Beijing📍 Beijing Peking University People's Hospital · Tests: Ponatinib, Azacitidine, Venetoclax, Olverembatinib MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) NCT07362225n/a2 sites📍 Chicago📍 New York MPN Research Foundation Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) NCT05322850Phase 1, Phase 24 sites📍 Gainesville📍 Miami📍 Miami University of Florida · Tests: Orca-Q Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy